[Combination therapy with Anastrozole and 5'-DFUR as a treatment for metastatic breast cancer].
For metastatic breast cancer patients who have hormone receptor-positive tumors, hormonal therapy aiming at optimal palliation and prolongation of life is the initial treatment of choice. To enhance the effect of hormonal monotherapy, a combination therapy with Anastrozole 1 mg po and 5'-DFUR 800 mg po daily was given to 11 patients with metastatic breast cancer. At a median follow-up period of 15 months, the overall response rate was 45.5%. The median duration of response in responders was 25 months. The overall median survival for the entire series was 15 months after the start of treatment. No patients complained of adverse events of grade 2 and over. This combination therapy with good response and little side effects is useful for metastatic breast cancer patients.
Miyoshi
Kazuya
K
Dept. of Surgery, National Hospital Organization, Fukuyama Medical Center.
Ohtsuka
Shinya
S
Inagaki
Masaru
M
Ohsaki
Toshihide
T
Fuchimoto
Sadanori
S
Yumura
Masahito
M
Nakagawa
Tomio
T
D000368:Aged; D000369:Aged, 80 and over; D000077384:Anastrozole; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D004334:Drug Administration Schedule; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009570:Nitriles / Q000008:administration & dosage; D017698:Postmenopause; D011960:Receptors, Estrogen / Q000032:analysis; D015996:Survival Rate; D014230:Triazoles / Q000008:administration & dosage
D009570:Nitriles; D011960:Receptors, Estrogen; D014230:Triazoles; D005467:Floxuridine; D000077384:Anastrozole; C025034:doxifluridine